Request for Expressions of Interest: Fault Detection Algorithms for Risk Mitigation in Artificial Pancreas Systems
EOI Submission Deadline: January 2, 2013
JDRF is launching an initiative to accelerate the development of algorithm-based approaches to detect and mitigate failure events in the components of artificial pancreas systems. These components include continuous glucose monitors, pumps and infusion sets. JDRF is soliciting Expressions of Interest (EOIs). Based on these EOIs, potential applications will be subsequently invited to be developed and submitted as full proposals.
In 2006, JDRF launched its Artificial Pancreas Project to accelerate the development of commercially available closed-loop systems. Since then, significant progress has been made in developing and testing algorithmic approaches to automate insulin delivery and clinical studies have progressed to the outpatient pilot setting. To achieve improved control and ultimately euglycemia, it is critically important that these systems not only maintain blood glucose within the target range but also mitigate the risk of system-based errors that would lead to unneeded dosing of insulin and hypoglycemia. In this call, JDRF intends to fund innovative approaches to detect such events that could occur through failure in hardware, software, mechanics or electronics, or a combination of the above and could be readily incorporated into future commercial artificial pancreas systems.
The objective of this initiative is to identify algorithmic approaches that mitigate system errors and ensure reliability and efficacy of artificial pancreas systems.
Examples of pertinent risks for algorithm-based detection/mitigation include:
Glucose sensor failures – degradation, dropouts, dislodgement
Bumpless transfer during sensor recalibration and new sensor insertions (changing between auto and manual) Insulin pump or infusion set failures - occlusions, dislodgement
Wireless communication interruption or failure
Unexpected user actions (eg.calibration error, miscalculated insulin delivery)
Projects may request a maximum of $1,000,000 USD of milestone-based funding for up to 2 years. Since the nature and scope of research supported by this initiative may vary, the budget and length of awards may vary. Indirect costs may not exceed 10% of the direct costs.
Applications may be submitted by for-profit entities as well as nonprofit organizations, public and private universities, colleges, hospitals, laboratories, units of state and local governments. There are no citizenship requirements.
EXPRESSION OF INTEREST
An approved EOI is required prior to submission of a full proposal.
New York, NY 10004
Phone: (800) 533-CURE (2873)
Fax: (212) 785-9595